Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: May 9, 2023
Reporting Period: First quarter ended March 31, 2023
This filing serves as a notification that the Company issued a press release regarding its financial results for the first quarter of 2023. The detailed financial data is contained in Exhibit 99.1 (Press Release), which is incorporated by reference but not explicitly detailed in the text of this 8-K form.
Key Financial Metrics
The text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the press release furnished as Exhibit 99.1.
Material Changes
No specific material changes versus the prior comparable period are quantified in this document. The filing indicates that a conference call was held to present business and financial results, implying a discussion of performance trends, but the specific variances are not listed in the 8-K text.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions, identified by terms such as "believe," "expect," and "anticipate."
- Outlook: No specific numerical guidance or updated outlook figures are provided in this text.
- Risks: The Company directs investors to Item 1A, "Risk Factors," in its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, for a comprehensive list of risks and uncertainties.
- Legal Disclaimer: Information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 9, 2023) for specific Q1 2023 revenue, net income, and cash flow figures.
- Access the archived webcast on the Company's website (www.supernus.com) for management's commentary on the results.
- Consult the Form 10-K for the year ended December 31, 2022 for detailed risk factors referenced in this filing.
- Verify the Company's status as an emerging growth company (indicated as not applicable in this filing).